Related Experiment Video
Updated: Aug 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Metabolic complications associated with antiretroviral therapy
R G Jain1, E S Furfine, L Pedneault
1Department of Metabolic Diseases, GlaxoSmithKline Inc., 5 Moore Drive, 27709, Research Triangle Park, NC, USA.
Insights
Highly active antiretroviral therapy (HAART) reduces AIDS mortality but can cause metabolic complications like lipodystrophy. These side effects vary by drug, patient factors, and duration of treatment.
Area of Science:
- Internal Medicine
- Pharmacology
- Infectious Diseases
Background:
- Highly active antiretroviral therapy (HAART) has decreased mortality in HIV-infected patients.
- Chronic HAART use is linked to long-term metabolic complications, including hyperlipidemia, fat redistribution, and diabetes mellitus, collectively termed lipodystrophy syndromes.
- These metabolic issues can occur independently, suggesting multiple distinct syndromes associated with HAART.
Purpose of the Study:
- To review current clinical and scientific information on metabolic complications associated with HAART.
- To examine hypotheses explaining the pathogenesis of these syndromes.
- To comment on current management strategies for these metabolic side effects.
Main Methods:
- Review of recent clinical trials.
- Analysis of cell culture and animal studies.
- Examination of scientific literature on antiretroviral therapy and metabolic complications.
Main Results:
- Metabolic complications such as hyperlipidemia and fat redistribution can occur independently and are associated with multiple antiretroviral drug classes (PIs, NRTIs, NNRTIs).
- Combination therapy (PI and NRTI) accelerates these syndromes.
- The incidence and type of metabolic complications vary among antiretroviral agents within the same class and can be influenced by infection duration, genetics, and environmental factors.
Conclusions:
- While HAART increases the risk of metabolic complications, its survival benefits outweigh these risks.
- Understanding the varied mechanisms and drug-specific effects is crucial for managing these side effects.
- Further research into management strategies is warranted.
Abstract:
Mortality rates in the HIV-infected patient population have decreased with the advent of highly active antiretroviral therapy (HAART) for the treatment of AIDS. Due to the chronic nature of HAART, long-term metabolic complications are associated with therapy, such as hyperlipidemia, fat redistribution and diabetes mellitus. Currently, all of these symptoms are classified as the lipodystrophy (LD) syndrome(s). However, hyperlipidemia and fat redistribution occur independently, indicating there may be multiple syndromes associated with HAART. Although fat gain/loss and dyslipidemia occur in protease inhibitor (PI) naïve patients treated with nucleoside reverse transcriptase inhibitors (NRTIs), combination therapies (PI and NRTI) accelerate the syndrome. Recent clinical trials, cell culture and animal studies indicate that these effects are not drug class specific and select PIs, NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) can be associated with metabolic complications. Moreover, the effects can vary between various members of the same class of antiretroviral agents (i.e. not all PIs cause the same adverse reactions) and may be influenced by duration of infection, genetics and environmental factors. Although HAART increases the risk of metabolic complications, this does not outweigh the benefits of survival. In this review, we summarize the latest clinical and scientific information on these metabolic complications, examine current hypotheses explaining the syndromes and comment on the existing methods available to manage these metabolic side effects.
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Hemodialysis II: Procedure and Complications
Chronic Kidney Disease II: Clinical Manifestations
Cryptococcal Meningitis
Complications of Diabetes Mellitus

